1. Home
  2. INTS vs TELA Comparison

INTS vs TELA Comparison

Compare INTS & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • TELA
  • Stock Information
  • Founded
  • INTS 2012
  • TELA 2012
  • Country
  • INTS United States
  • TELA United States
  • Employees
  • INTS N/A
  • TELA N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • TELA Medical/Dental Instruments
  • Sector
  • INTS Health Care
  • TELA Health Care
  • Exchange
  • INTS Nasdaq
  • TELA Nasdaq
  • Market Cap
  • INTS 30.8M
  • TELA 36.4M
  • IPO Year
  • INTS 2023
  • TELA 2019
  • Fundamental
  • Price
  • INTS $0.54
  • TELA $1.08
  • Analyst Decision
  • INTS Strong Buy
  • TELA Strong Buy
  • Analyst Count
  • INTS 3
  • TELA 4
  • Target Price
  • INTS $8.50
  • TELA $6.00
  • AVG Volume (30 Days)
  • INTS 362.2K
  • TELA 86.3K
  • Earning Date
  • INTS 05-20-2025
  • TELA 05-08-2025
  • Dividend Yield
  • INTS N/A
  • TELA N/A
  • EPS Growth
  • INTS N/A
  • TELA N/A
  • EPS
  • INTS N/A
  • TELA N/A
  • Revenue
  • INTS N/A
  • TELA $69,300,000.00
  • Revenue This Year
  • INTS N/A
  • TELA $25.90
  • Revenue Next Year
  • INTS N/A
  • TELA $23.00
  • P/E Ratio
  • INTS N/A
  • TELA N/A
  • Revenue Growth
  • INTS N/A
  • TELA 18.56
  • 52 Week Low
  • INTS $0.50
  • TELA $0.87
  • 52 Week High
  • INTS $5.28
  • TELA $6.50
  • Technical
  • Relative Strength Index (RSI)
  • INTS 18.34
  • TELA 47.00
  • Support Level
  • INTS $0.55
  • TELA $0.93
  • Resistance Level
  • INTS $0.59
  • TELA $1.07
  • Average True Range (ATR)
  • INTS 0.12
  • TELA 0.08
  • MACD
  • INTS -0.02
  • TELA 0.05
  • Stochastic Oscillator
  • INTS 4.71
  • TELA 82.38

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: